[{"address1": "4149 Liberty Canyon Road", "city": "Agoura Hills", "state": "CA", "zip": "91301", "country": "United States", "phone": "805 730 0360", "website": "https://www.acelyrin.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.", "fullTimeEmployees": 135, "companyOfficers": [{"maxAge": 1, "name": "Ms. Mina  Kim J.D.", "age": 50, "title": "CEO & Director", "yearBorn": 1974, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tyler  Marciniak", "title": "Vice President of Investor Relations, Communications & Corporate Operations", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. K. Amar Murugan J.D.", "age": 48, "title": "Chief Legal Officer", "yearBorn": 1976, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly  Chow", "title": "Chief People Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kenneth A. Lock", "age": 50, "title": "Chief Commercial Officer", "yearBorn": 1974, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shephard  Mpofu M.D.", "title": "Chief Medical Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Patricia A. Turney", "age": 57, "title": "Chief Technical Operations Officer", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 4, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1738368000, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.17, "open": 2.55, "dayLow": 2.365, "dayHigh": 2.64, "regularMarketPreviousClose": 2.17, "regularMarketOpen": 2.55, "regularMarketDayLow": 2.365, "regularMarketDayHigh": 2.64, "payoutRatio": 0.0, "forwardPE": -1.2264152, "volume": 12531513, "regularMarketVolume": 12531513, "averageVolume": 1700354, "averageVolume10days": 4432530, "averageDailyVolume10Day": 4432530, "bid": 1.88, "ask": 3.03, "bidSize": 2, "askSize": 2, "marketCap": 260847584, "fiftyTwoWeekLow": 1.845, "fiftyTwoWeekHigh": 8.885, "fiftyDayAverage": 2.5936, "twoHundredDayAverage": 4.403625, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -337284512, "profitMargins": 0.0, "floatShares": 72214345, "sharesOutstanding": 100326000, "sharesShort": 5868409, "sharesShortPriorMonth": 6141478, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0585, "heldPercentInsiders": 0.088199995, "heldPercentInstitutions": 0.99693, "shortRatio": 3.44, "shortPercentOfFloat": 0.066700004, "impliedSharesOutstanding": 100326000, "bookValue": 5.286, "priceToBook": 0.4918653, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -264404992, "trailingEps": -2.46, "forwardEps": -2.12, "enterpriseToEbitda": 0.904, "52WeekChange": -0.7071525, "SandP52WeekChange": 0.2021538, "quoteType": "EQUITY", "currentPrice": 2.6, "targetHighPrice": 20.0, "targetLowPrice": 3.0, "targetMeanPrice": 10.33333, "targetMedianPrice": 8.0, "recommendationMean": 1.75, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 562372992, "totalCashPerShare": 5.605, "ebitda": -373011008, "totalDebt": 7382000, "quickRatio": 7.098, "currentRatio": 7.147, "debtToEquity": 1.397, "returnOnAssets": -0.32891998, "returnOnEquity": -0.41946998, "freeCashflow": -192560000, "operatingCashflow": -255968992, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "SLRN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "ACELYRIN, INC.", "marketState": "POST", "corporateActions": [], "postMarketTime": 1740171712, "regularMarketTime": 1740171600, "exchange": "NMS", "messageBoardId": "finmb_698766339", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 19.81566, "regularMarketPrice": 2.6, "postMarketChange": 0.0, "regularMarketChange": 0.42999983, "regularMarketDayRange": "2.365 - 2.64", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1700354, "fiftyTwoWeekLowChange": 0.7549999, "fiftyTwoWeekLowChangePercent": 0.40921402, "fiftyTwoWeekRange": "1.845 - 8.885", "fiftyTwoWeekHighChange": -6.2850003, "fiftyTwoWeekHighChangePercent": -0.707372, "fiftyTwoWeekChangePercent": -70.71525, "earningsTimestampStart": 1743192000, "earningsTimestampEnd": 1743883200, "earningsCallTimestampStart": 1731533400, "earningsCallTimestampEnd": 1731533400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.46, "epsForward": -2.12, "epsCurrentYear": -2.44093, "priceEpsCurrentYear": -1.0651678, "fiftyDayAverageChange": 0.00639987, "fiftyDayAverageChangePercent": 0.0024675624, "twoHundredDayAverageChange": -1.8036251, "twoHundredDayAverageChangePercent": -0.40957737, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2023-05-05", "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "longName": "Acelyrin, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1683207000000, "postMarketChangePercent": 0.0, "postMarketPrice": 2.6, "displayName": "Acelyrin", "trailingPegRatio": null, "__fetch_time": "2025-02-21"}]